Rise Therapeutics Announces FDA Clearance of its IND Application to ...
Rise Therapeutics received FDA clearance for its IND application to start a Phase 1 trial of R-3750, an oral immunotherapy for ulcerative colitis. R-3750 targets gut inflammation using a synthetic biology approach, aiming to treat IBD by engaging dendritic cells. The trial will assess safety, tolerability, and clinical activity in 36 participants.
Reference News
Rise Therapeutics Announces FDA Clearance of its IND Application to ...
Rise Therapeutics received FDA clearance for its IND application to start a Phase 1 trial of R-3750, an oral immunotherapy for ulcerative colitis. R-3750 targets gut inflammation using a synthetic biology approach, aiming to treat IBD by engaging dendritic cells. The trial will assess safety, tolerability, and clinical activity in 36 participants.